Patent Landscape and Technological Trajectory of Drug Delivery Systemsfor Overcoming Drug Resistance in Non-small Cell Lung Cancer

Widespread drug resistance in the treatment of non-small cell lung cancer (NSCLC) seriously restricts clinical efficacy, so the development of new drug delivery systems to overcome drug resistance has become a key area of research. Currently, no systematic study has been conducted on anti-drug resistance drug delivery systems for NSCLC. This study systematically analyzed patent application trends and delivery system types for drug resistance in NSCLC over the past two decades using the WIPO, Espacenet, and Incopat global patent databases. The analysis focused on the evolution of delivery technology and the value and effectiveness of related technologies. The results showed that the number of patent applications has grown continuously, reflecting progressive innovation in this field of technology from basic research and development to breakthrough applications. The main technology types are nano delivery (56.6% of total patents) and coupled delivery (28.3%). Additionally, emerging technologies such as exosomes, vesicles, and siRNA have emerged. There has been a leap in technology evolution from single-carrier development to intelligent, responsive delivery. In recent years, research has focused on the synergistic application of stimuli-responsive nano systems and combination therapy. High-value patents typically offer the combined benefits of various technologies and mechanisms, particularly in terms of overcoming drug resistance, achieving precise delivery, and reducing toxic side effects. This study provides an important theoretical basis and practical guidance for optimizing the research and development (R&D) strategy and patent portfolio for anti-drug-resistance drug delivery technology in NSCLC.